FLUOCINONIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Fluocinonide is a potent corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced prostaglandin and leukotriene synthesis. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Topically applied fluocinonide is absorbed into the skin and metabolized primarily in the liver via CYP3A4 and other enzymes, with subsequent conjugation and excretion in urine and bile. |
| Excretion | Primarily hepatic metabolism; inactive metabolites excreted renally and fecally. Renal elimination accounts for approximately 60-70% of total clearance, fecal elimination ~30-40%. Less than 1% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is approximately 1.3-2.4 hours in plasma. Clinically, due to high tissue binding and slow release from skin, the pharmacodynamic half-life for topical effect may extend to 12-24 hours. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Volume of distribution is 0.2-0.3 L/kg. This low Vd reflects high plasma protein binding and limited extravascular distribution. |
| Bioavailability | Topical: Systemic bioavailability after topical application is 1-5% under normal conditions, but increases to up to 36% with occlusive dressings or on inflamed skin. Oral bioavailability is negligible as not used systemically. |
| Onset of Action | Topical: Onset of anti-inflammatory effect occurs within 2-3 hours; vasoconstriction (blanching) detectable by 1-2 hours. No data for other routes; not administered systemically. |
| Duration of Action | Duration of therapeutic effect after topical application is typically 12-24 hours. Duration may be extended with occlusive dressings. Clinical response sustained with once or twice daily dosing. |
Topical: Apply a thin film to affected area 1-3 times daily. Limitation of use: Should not exceed 60 g per week in adults.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment; systemic absorption is minimal with topical use. |
| Liver impairment | No formal studies conducted; use with caution in severe hepatic impairment due to potential for increased systemic exposure if applied to large areas or under occlusion. |
| Pediatric use | Topical: Apply a thin film to affected area 1-2 times daily. Limit treatment duration to 2 weeks and avoid use under occlusion or on large body surface areas due to increased risk of HPA axis suppression. |
| Geriatric use | Use the lowest effective dose for the shortest duration; avoid prolonged use or application to large areas due to increased risk of skin atrophy and HPA axis suppression. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Systemic absorption can occur with extensive use.
| Breastfeeding | Systemic corticosteroids appear in breast milk, but topical application of fluocinonide is expected to result in minimal transfer. M/P ratio not established. Use with caution on small areas, short-term, and avoid application to breasts or nipples. Consider applying after nursing and allow absorption before next feed. |
| Teratogenic Risk | Topical fluocinonide is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects (cleft palate, skeletal anomalies) with systemic corticosteroids at high doses. There are no adequate human studies. Topical application may result in minimal systemic absorption, but risks cannot be excluded. First trimester: avoid unless essential. Second and third trimesters: use lowest potency and shortest duration. Potential fetal risks include low birth weight and adrenal suppression if prolonged high-dose use. |
■ FDA Black Box Warning
None.
| Common Effects | Skin atrophy |
| Serious Effects |
Hypersensitivity to fluocinonide or any component of the formulation; untreated bacterial, fungal, or viral skin lesions; perioral dermatitis; rosacea; acne vulgaris.
| Precautions | Topical corticosteroids can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Systemic absorption may occur especially with prolonged use, use over large areas, or under occlusive dressings. Pediatric patients may be more susceptible to systemic toxicity. Local adverse reactions include skin atrophy, striae, telangiectasias, and secondary infections. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose (especially if preeclampsia or gestational diabetes risk), and signs of adrenal suppression (e.g., fatigue, hypotension) if prolonged use over large surface areas. Fetal monitoring may include growth scans if long-term high-potency use. |
| Fertility Effects | No known direct impact on fertility in humans. High-dose systemic corticosteroids may cause menstrual irregularities or suppress ovulation, but topical fluocinonide is unlikely to affect fertility due to minimal systemic absorption. |